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order to predict the efﬁcacy of the vaccine in the Malaysian
population.
Methods: A total of 217 strains of S. pneumoniae obtained
from invasive (blood, CSF, pleural ﬂuid) and non-invasive
sites (respiratory sites) of both pediatric and adult patients
were serotyped by the method of Pai et al (2006). Strains
were identiﬁed by standard methods and their antibiotic
resistance proﬁle determined by agar dilution method (PEN,
ERY, CRO, CTX, CXM, CIP, GAT, MOX, LVX) and disk diffusion
(PEN, ERY, CRO, CXM, AMC, AMP, VAN, SXT, CL, CN10, DA, OX,
CIP). Seven different multiplex PCRs were used to deter-
mine the following serotypes/serogroups: 1, 2, 3, 4, 5, 8,
13, 14, 20, 21, 31, 34, 37, 38, 39, 40, 44, 46, 6A, 7A, 7B, 7C,
7F, 9A, 9N, 9L, 9L, 10A, 10F, 11A, 11D, 11F, 12A, 12B, 12F,
15A, 15B, 15C, 15F, 16A, 16F, 17F, 33A,35B, 35F, 35A, 35C,
and 47F. The cps operon was used as the internal positive
control.
Results: Of the 217 strains, there were 22.6% PRSP, 27.7%
PISP and 49.8% PSSP strains based on their susceptibility to
penicillin. Serotypes detected were the 19F, 18C, 15B/C,
23F, 6A/B, 10A, 12A/F, 3, 14, 11A/D, 34, 19A, 16F, 35F/47F,
and 7F/A. The most predominant serotype was 19F and it
was also predominant in isolates obtained from invasive
sites. Serotype 19F and 23F were observed to be common
among the PRSP strains, with 35/49 strains serotyped as
19F while 13/49 strains were serotyped as 23F. Only one
PRSP strain was serotyped as 34. Serotype 19F was also pre-
dominant among the PISP strains. Other serotypes detected
among the PISP strains were 6A/B, 11A/D, 23F and 14. How-
ever, the distribution of these serotypes were rare. The PSSP
strains showed to have other serotypes such as 18C, 15B/C,
6A/B, 10A, 19A, 3, 14, 16F, & 7B/C, 7F and 35F/47F. The dis-
tribution of serotype 19F and 23F was rare among this group
of isolates.
Conclusion: In conclusion, we observe serotype 19F and
23F to be prevalent among the penicillin resistant strains,
which has been included in the 7-valent conjugate vaccine.
Therefore, the efﬁcacy of this vaccine should be effective
in our population. However, it is not possible to predict
serotypes that might become predominant in the future.
doi:10.1016/j.ijid.2008.05.713
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Background: One may treat MRSA infections by combina-
tion of vancomycin (VCM) with -lactam antibiotics. Such a
combination therapy, however, often causes emergence of
VCM-resistant MRSA. The mechanism of this phenomenon,
-lactam antibiotic-induced VCM-resistance (BIVR), is the
subject of our investigation to be elucidated. Currently up to
20% of blood isolated MRSA are found to be BIVR strains. Here
we report the accelerated consumption of free VCM by the
presence of a -lactam antibiotic that leads VCM-resistance
in BIVR strains.
Methods: A representative BIVR strain, BIVR744 (MIC:
VCM 4mg/L), was selected under various rationale and
used throughout the experiments. Free VCM in the medium
was quantiﬁed by a competitive-ELISA that enabled us to
detect the decrease of free VCM at the level of 0.1g/mL.
Morphological changes of cells grown with VCM and those
with VCM+ceftizoxime (CZX) were compared by electron
microscopy. Penicillin binding proteins (PBPS) 2 and 2′ were
determined by the ﬂuorescent method.
Results: Growth of BIVR744 in the presence of 4mg/L
VCM took 27 h to reach A578 = 1.0, whereas it was only 8 h
under coexistence of 1mg/L CZX. Without CZX, free VCM
remained >2.1mg/L in the ﬁrst 24 h and the growth was
inhibited. On the other hand, in the presence of 1mg/L
CZX, VCM decreased to 0.5mg/L at 8 h resulting the growth
to A578 = 1.44. During inhibited by VCM, thickened cell walls
were observed in both cells cultivated with and without CZX,
however, the grown cells in the presence of CZX showed nor-
mal morphology. CZX showed no effect on the amount of
PBP2 and 2′ although BIVR 744 contains large quantities of
them.
Conclusion: It was concluded that the BIVR phenomenon
is attributable to the accelerated VCM consumption by coex-
isted -lactam antibiotics.
doi:10.1016/j.ijid.2008.05.714
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Background: Resistance (R) to penicillin (PEN),
macrolides, and other commonly prescribed agents used
to treat community-acquired respiratory tract infections
caused by S. pneumoniae (SP) has become prevalent. Often,
these organisms can be multi-drug resistant (MDR) which
is especially problematic for clinicians. Investigation of
regional trends in susceptibility (S) patterns and careful
consideration of MDR prevalence can provide useful infor-
mation for empiric treatment. The GLOBAL Surveillance
program was designed to monitor the S patterns of SP on a
regional level.
Methods: During 2007, 1547 SP were collected from 5
countries in Europe (EU; France [FR], Germany [GE], Italy
[IT], Spain [SPN], Belgium [BG], and the United Kingdom
[UK] and 554 SP were collected from 4 regions in Asia (AS;
Hong Kong [HK], South Korea [SK], China [CH], and Taiwan
[TW]). All isolates were centrally tested by broth microdilu-
tion (CLSI M7-A7, 2006) against levoﬂoxacin (LFX) and 12
comparator agents. MIC results were interpreted accord-
ing to CLSI M100-S17, 2007. For SP, MDR was deﬁned as
R to ≥2 of the following agents: PEN, cefuroxime (CFX),
erythromycin (ERY), tetracycline (TET), and trimethoprim-
sulfamethoxazole (SXT).
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Results: Overall, among SP isolates in AS and EU respec-
tively, S rates were 39.2 and 75.2% for PEN; 45.5 and 82.5%
for CFX; 21.1 and 67.4% for ERY; 19.3 and 75.6% for TET;
37.2 and 74.6% for SXT; and 98.0 and 98.8% for LFX. For all
countries combined the prevalence of MDR SP was 77.4% in
AS and 29.1% in EU. The most prevalent MDR phenotype in
AS was 5-drug R (including PEN, ERY, CFX, TET, and SXT) and
in EU it was 2-drug R (including ERY and TET). Among MDR
isolates, 97.4% in AS and 97.8% in EU were S to LFX. By coun-
try, the MDR rates (%) in EU were as follows: 42.7 FR; 37.9 IT;
37.2 SPN; 26.7 BG; 16.1 GE; and 9.4 UK. Comparatively, the
MDR rates in AS by region were dramatically higher (66.9%
HK, 76.7% SK, 85.6% CH, and 90.6% TW).
Conclusions: Decreased S among many commonly utilized
respiratory agents against SP, in particular beta-lactams and
macrolides, continues to be an issue in both EU and AS. How-
ever, SP remained >98% S to LFX in both regions. MDR rates
among SP is also a concern in AS (77%) and EU (29%), although
rates varied by country. Continued surveillance on a regional
basis is warranted to monitor changes in S among SP and to
help guide local empiric therapy.
doi:10.1016/j.ijid.2008.05.715
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Background: The Tigecycline In-Vitro Surveillance in Tai-
wan (TIST), initiated in 2006, is a nationwide surveillance
program designed to monitor longitudinally the in vitro
activities of tigecycline against commonly encountered
resistant bacteria in Taiwan. This study, part of TIST-2006
study, aims to compare the in vitro activities of tigecycline
against clinical isolates of Gram-positive bacteria.
Methods: A total of 805 isolates of Gram-positive bacte-
ria were collected from various sources of patients treated
at 20 teaching hospitals. Minimum inhibitory concentrations
(MICs) for tigecycline of these isolates were determined by
the broth microdilution methods according the guidelines
described by Clinical and Laboratory Standards Institute
(CLSI) and the E test as manufacturer’s description. Suscep-
tibility results of tigecycline were interpreted by the MIC
criteria provided by U.S. FDA. Agreement and error analysis
of results generated by two methods were also evaluated.
Results: Susceptibility results of tigecycline are summa-
rized in the table 1. Agreement of two methods was low:
70.8% for MRSA, 26.4% for S. pneumoiae, 20.5% for other
Streptococcus species, and 30.7% for VRE. There was no very
major or major error noted.
Conclusion: Tigecycline exhibited excellent in vitro activ-
ities against gram-positive cocci, including MRSA, VRE,
and penicillin-nonsusceptible S. pneumoiae (PNSSP) isolates
in Taiwan. Correlations between MIC values using broth
microdilution and the E test methods for these organisms
were poor.
doi:10.1016/j.ijid.2008.05.716
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Background: There is evidence that hetero-resistance
may be associated with failure of vancomycin therapy. Most
routine MIC testing methods used in diagnostic laborato-
ries do not detect hVISA strains. There are few published
Canadian studies using other methods for this purpose.
Objective: To use the Macro E-test method and the Gly-
copeptide Resistance Detection (GRD) E-test (AB Biodisk,
Sweden)to assess the prevalence of hVISA among the bac-
teremic isolates of S. aureus at a tertiary care centre in
Canada.
Methods: Ninety two isolates of S. aureus including 7
Methicillin Resistant S. aureus (MRSA) from BSI were tested
by standard, Macro E-test and GRD methods. For the stan-
dard E-test, the organism was tested at 0.5 McFarland on
Mueller Hinton (MH)Agar, and incubated for 24 hours at 35 ◦C.
For Macro E-test, 100l of a 2.0 McFarland suspension was
used on BHI Agar incubated for 48 hours at 35 ◦C. For GRD,
0.5 McFarland inoculum was tested on MH with 5% blood,
incubated for 48 hours at 35 ◦C.A strain was deﬁned as hVISA
if it had an MIC of (>) 8g/ml for vancomycin and teicoplanin
by Macro or GRD E-test.
Results: All the isolates were sensitive to vancomycin
and teicoplanin, when tested by the standard method. The
MIC50 and MIC90 were: vancomycin 1.0g/ml and 1.5g/ml;
teicoplanin 0.5g/ml and 0.75g/ml. Though hVISA was
not detected among the 92 strains tested by Macro E-test
method as per the deﬁned criteria, some strains showed
increased MICs (6.0g/ml). MIC50 and MIC90 were: van-
comycin 3.0g/ml and 6.0g/ml; teicoplanin 3.0g/ml
and 6.0g/ml.The MIC50 and MIC90 by GRD were: van-
comycin 1.0g/ml and 1.5g/ml; teicoplanin 2.0g/ml and
3.0g/ml.
